Names | |
---|---|
IUPAC name (2Z)-2-[(3R,4S,5S,6R,7R,8S,9S,10R,13R,14S,16S)-6,16-diacetyloxy-3,7-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoic acid | |
Other names Acremonic acid | |
Identifiers | |
3D model (JSmol) | |
ChEMBL | |
PubChem CID | |
UNII | |
| |
| |
Properties | |
C33H50O8 | |
Molar mass | 574.755 g·mol−1 |
Density | g/cm³ |
poorly soluble [1] | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). |
Cephalosporin P1 is a naturally occurring antibiotic compound belonging to the cephalosporin class, which was first isolated from the fungus Cephalosporium acremonium (later reclassified as Acremonium chrysogenum ) [2] . It is one of the early cephalosporins discovered, alongside cephalosporin C and other related metabolites.
Fusidane-type antibiotics are a class of triterpenoid antibiotics that include helvolic acid, fusidic acid, and cephalosporin P1. [3] Among these, fusidic acid is notable for its clinical use in treating bacterial infections. [4]
Unlike later-generation cephalosporins used clinically, cephalosporin P1 has limited therapeutic use due to its weaker antibacterial activity.
Cephalosporin P1 demonstrated strong effectiveness against methicillin-sensitive Staphylococcus aureus , methicillin-resistant S. aureus, and vancomycin-intermediate S. aureus strains. [5]